RxDoctor Payments Data

Erin Taveras

Surgical · Stony Brook, NYNPI 1134309883

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 413 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by AbbVie at 39.4% of the total. Among surgical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,703in general payments, 2019–2025

Across 413 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Harmony Biosciences LLC$756
  • Lundbeck LLC$689
  • Pfizer$436
  • Scilex Pharmaceuticals Inc.$265
  • Amneal Pharmaceuticals LLC$261
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$7,64899%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,703 in reported general payments places this provider in the 95th percentile of 1,544 surgical providers in New York.

See all surgical providers in New York

Medicare billing

Part B allowed, 2024
$1,412
Medicare patients
13
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate27$39,760
UbrelvyUbrogepant17$26,749
QuliptaAtogepant23$25,749
Aimovig AutoinjectorErenumab-Aooe11$7,645
Pregabalin46$1,276
Gabapentin96$914
Memantine Hcl16$364
Donepezil Hcl47$223
Clonazepam11$175
Nortriptyline Hcl19$115
Tizanidine Hcl12$82
Cyclobenzaprine Hcl23$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$3,035$52,49840 claims
PfizerNurtec Odt$436$39,76027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,544 surgical providers in New York.

Other surgical in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →